Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events-Reply

JAMA Oncol. 2021 Oct 1;7(10):1574-1575. doi: 10.1001/jamaoncol.2021.2957.

Authors

Douglas B Johnson¹, J Randall Patrinely Jr², Fei Ye³

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt University School of Medicine, Nashville, Tennessee.
³ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

PMID: 34383022
DOI: 10.1001/jamaoncol.2021.2957

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immunologic Factors
Immunotherapy* / adverse effects
Nivolumab*

Substances

Immunologic Factors
Nivolumab